154 related articles for article (PubMed ID: 15861669)
21. [Complement regulatory factors and immunologic recognition mechanism between species].
Seya T; Matsunoto M
Nihon Rinsho Meneki Gakkai Kaishi; 1995 Dec; 18(6):637-42. PubMed ID: 8963770
[No Abstract] [Full Text] [Related]
22. Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins.
Gasque P; Thomas A; Fontaine M; Morgan BP
J Neuroimmunol; 1996 May; 66(1-2):29-40. PubMed ID: 8964911
[TBL] [Abstract][Full Text] [Related]
23. K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement.
Jurianz K; Ziegler S; Donin N; Reiter Y; Fishelson Z; Kirschfink M
Int J Cancer; 2001 Sep; 93(6):848-54. PubMed ID: 11519047
[TBL] [Abstract][Full Text] [Related]
24. Glomerulonephritis and complement regulatory proteins.
Nangaku M; Johnson RJ; Couser WG
Exp Nephrol; 1997; 5(5):345-54. PubMed ID: 9386969
[No Abstract] [Full Text] [Related]
25. Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins.
Sohn JH; Kaplan HJ; Suk HJ; Bora PS; Bora NS
Invest Ophthalmol Vis Sci; 2000 Oct; 41(11):3492-502. PubMed ID: 11006244
[TBL] [Abstract][Full Text] [Related]
26. Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases.
Miwa T; Song WC
Int Immunopharmacol; 2001 Mar; 1(3):445-59. PubMed ID: 11367529
[TBL] [Abstract][Full Text] [Related]
27. Upregulation of complement regulators MCP (CD46), DAF (CD55) and protectin (CD59) in arthritic joint disease.
Davies ME; Horner A; Loveland BE; McKenzie IF
Scand J Rheumatol; 1994; 23(6):316-21. PubMed ID: 7528443
[TBL] [Abstract][Full Text] [Related]
28. Protection of xenogeneic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCP.
Huang J; Gou D; Zhen C; Jiang D; Mao X; Li W; Chen S; Cai C
FEMS Immunol Med Microbiol; 2001 Oct; 31(3):203-9. PubMed ID: 11720816
[TBL] [Abstract][Full Text] [Related]
29. Expression of complement regulating proteins on FDC.
Schgmitz J; Petrasch S; Mews I; van Lunzen J; Kluxen B; Würzner R; Schmitz H; Racz P
Adv Exp Med Biol; 1995; 378():293-5. PubMed ID: 8526076
[No Abstract] [Full Text] [Related]
30. Complement regulatory molecules on human myelin and glial cells: differential expression affects the deposition of activated complement proteins.
Koski CL; Estep AE; Sawant-Mane S; Shin ML; Highbarger L; Hansch GM
J Neurochem; 1996 Jan; 66(1):303-12. PubMed ID: 8522968
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
[TBL] [Abstract][Full Text] [Related]
32. Functional domains, structural variations and pathogen interactions of MCP, DAF and CR1.
Hourcade D; Liszewski MK; Krych-Goldberg M; Atkinson JP
Immunopharmacology; 2000 Aug; 49(1-2):103-16. PubMed ID: 10904110
[TBL] [Abstract][Full Text] [Related]
33. CRISPR/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research.
Thielen AJF; van Baarsen IM; Jongsma ML; Zeerleder S; Spaapen RM; Wouters D
J Immunol Methods; 2018 May; 456():15-22. PubMed ID: 29447841
[TBL] [Abstract][Full Text] [Related]
34. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A.
Juhl H; Helmig F; Baltzer K; Kalthoff H; Henne-Bruns D; Kremer B
J Surg Oncol; 1997 Mar; 64(3):222-30. PubMed ID: 9121154
[TBL] [Abstract][Full Text] [Related]
35. Membrane-bound complement regulatory proteins as biomarkers and potential therapeutic targets for SLE.
Das N; Biswas B; Khera R
Adv Exp Med Biol; 2013; 735():55-81. PubMed ID: 23402019
[TBL] [Abstract][Full Text] [Related]
36. Protease-modified erythrocytes: CD55 and CD59 deficient PNH-like cells.
Yuan FF; Bryant JA; Fletcher A
Immunol Cell Biol; 1995 Feb; 73(1):66-72. PubMed ID: 7539403
[TBL] [Abstract][Full Text] [Related]
37. Altered Expression of Complement Regulatory Proteins CD35, CD46, CD55, and CD59 on Leukocyte Subsets in Individuals Suffering From Coronary Artery Disease.
Mishra N; Mohata M; Narang R; Lakshmy R; Hazarika A; Pandey RM; Das N; Luthra K
Front Immunol; 2019; 10():2072. PubMed ID: 31555286
[TBL] [Abstract][Full Text] [Related]
38. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein.
Kim YU; Kinoshita T; Molina H; Hourcade D; Seya T; Wagner LM; Holers VM
J Exp Med; 1995 Jan; 181(1):151-9. PubMed ID: 7528766
[TBL] [Abstract][Full Text] [Related]
39. Structure and flexibility of the multiple domain proteins that regulate complement activation.
Kirkitadze MD; Barlow PN
Immunol Rev; 2001 Apr; 180():146-61. PubMed ID: 11414356
[TBL] [Abstract][Full Text] [Related]
40. Cytokines affect resistance of human renal tumour cells to complement-mediated injury.
Blok VT; Gelderman KA; Tijsma OH; Daha MR; Gorter A
Scand J Immunol; 2003 Jun; 57(6):591-9. PubMed ID: 12791098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
